Mammalian Models of Duchenne Muscular Dystrophy: Pathological Characteristics and Therapeutic Applications

被引:63
|
作者
Nakamura, Akinori [1 ]
Takeda, Shin'ichi [2 ]
机构
[1] Shinshu Univ, Sch Med, Dept Med Neurol & Rheumatol, Matsumoto, Nagano 3908621, Japan
[2] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mol Therapy, Kodaira, Tokyo 1878502, Japan
来源
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY | 2011年
关键词
EXON-SKIPPING THERAPY; SKELETAL-MUSCLE; SYSTEMIC DELIVERY; CANINE MODEL; MDX MOUSE; EXPRESSION; GENE; MICE; DEGENERATION; RESTORATION;
D O I
10.1155/2011/184393
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Duchenne muscular dystrophy (DMD) is a devastating X-linked muscle disorder characterized by muscle wasting which is caused by mutations in the DMD gene. The DMD gene encodes the sarcolemmal protein dystrophin, and loss of dystrophin causes muscle degeneration and necrosis. Thus far, therapies for this disorder are unavailable. However, various therapeutic trials based on gene therapy, exon skipping, cell therapy, read through therapy, or pharmaceutical agents have been conducted extensively. In the development of therapy as well as elucidation of pathogenesis in DMD, appropriate animal models are needed. Various animal models of DMD have been identified, and mammalian (murine, canine, and feline) models are indispensable for the examination of the mechanisms of pathogenesis and the development of therapies. Here, we review the pathological features of DMD and therapeutic applications, especially of exon skipping using antisense oligonucleotides and gene therapies using viral vectors in murine and canine models of DMD.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Potential Therapeutic Action of Adiponectin in Duchenne Muscular Dystrophy
    Abou-Samra, Michel.
    Boursereau, Raphael
    Lecompte, Sophie
    Noel, Laurence
    Brichard, Sonia M.
    AMERICAN JOURNAL OF PATHOLOGY, 2017, 187 (07) : 1577 - 1585
  • [22] Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy
    Happi Mbakam, Cedric
    Lamothe, Gabriel
    Tremblay, Jacques P.
    FRONTIERS IN MEDICINE, 2022, 9
  • [23] Laminin-111: A Potential Therapeutic Agent for Duchenne Muscular Dystrophy
    Goudenege, Sebastien
    Lamarre, Yann
    Dumont, Nicolas
    Rousseau, Joel
    Frenette, Jerome
    Skuk, Daniel
    Tremblay, Jacques P.
    MOLECULAR THERAPY, 2010, 18 (12) : 2155 - 2163
  • [24] Muscular dystrophy: Experimental animal models and therapeutic approaches (Review)
    Gaina, Gisela
    Popa , Alexandra
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (06)
  • [25] Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy
    Moulton, Hong M.
    Moulton, Jon D.
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2010, 1798 (12): : 2296 - 2303
  • [26] Mutation-independent Proteomic Signatures of Pathological Progression in Murine Models of Duchenne Muscular Dystrophy
    van Westering, Tirsa L. E.
    Johansson, Henrik J.
    Hanson, Britt
    Coenen-Stass, Anna M. L.
    Lomonosova, Yulia
    Tanihata, Jun
    Motohashi, Norio
    Yokota, Toshifumi
    Takeda, Shin'ichi
    Lehtio, Janne
    Wood, Matthew J. A.
    EL Andaloussi, Samir
    Aoki, Yoshitsugu
    Roberts, Thomas C.
    MOLECULAR & CELLULAR PROTEOMICS, 2020, 19 (12) : 2047 - 2067
  • [27] Therapeutic approaches to muscular dystrophy
    Goyenvalle, Aurelie
    Seto, Jane T.
    Davies, Kay E.
    Chamberlain, Jeffrey
    HUMAN MOLECULAR GENETICS, 2011, 20 : R69 - R78
  • [28] Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy
    Aoki, Yoshitsugu
    Yokota, Toshifumi
    Wood, Matthew J. A.
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [29] Therapeutic Targeting of PTEN in Duchenne Muscular Dystrophy
    Parveen, Arshiya
    Wen, Yefei
    Roy, Anirban
    Kumar, Ashok
    MOLECULAR THERAPY, 2021, 29 (01) : 8 - 9
  • [30] A new therapeutic effect of fenofibrate in Duchenne muscular dystrophy: The promotion of myostatin degradation
    Sun, Zeren
    Xu, Dengqiu
    Zhao, Lei
    Li, Xihua
    Li, Sijia
    Huang, Xiaofei
    Li, Chunjie
    Sun, Lixin
    Liu, Bing
    Jiang, Zhenzhou
    Zhang, Luyong
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (06) : 1237 - 1250